Mederi Therapeutics Inc. designs, manufactures and markets products for the treatment of diseases or conditions that affect the human gastrointestinal tract. These products utilize low-power radiofrequency (RF) energy to remodel the sphincter muscle at either end of the digestive tract, thereby improving function, providing significant symptom relief, and dramatic improvement in quality-of-life. Mederi’s first two products, Stretta for GERD and Secca for bowel incontinence are used by, gastroenterologists (GI), general surgeons, ENTs, gynecologists, bariatric surgeons, colon and rectal surgeons, urogynecologists, and thoracic surgeons.
MEDERI acquired the Stretta and Secca systems, along with the intellectual property and other assets of the original developer in November of 2008. MEDERI has redesigned and re-launched all products for worldwide distribution. MEDERI products have FDA 510(k) clearance, a CE Mark, ISO13485, and are available in more than 40 countries.